Statin-intolerant patients need a different type of clinical trial

(Medical Xpress) -- Millions of people take statins, the blockbuster drug that lowers low-density lipoprotein (LDL), the so-called bad cholesterol. But as many as 20 percent of them develop adverse effects such as muscle fatigue and weakness and impaired cognition. Rockefeller University scientists Patricia Maningat and Jan L. Breslow, writing in this week’s issue of the New England Journal of Medicine, argue that clinical trials need to be designed to address the needs of statin-intolerant patients.

Read the whole article on Physorg

More from Physorg